Avatar

About Richard Knight

Dr Richard Knight PhD, ERT, is a Director and Co-founder of ApconiX, a preclinical toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts. Richard graduated from the University of Bradford in 1989 with a degree in Biomedical Sciences (Pharmacology) before gaining a PhD at the University of Leeds researching the role of adenosine receptors in renal function and toxicity. His research then included post-doctoral studies at University of California, Los Angeles (UCLA) into the effects of ischaemia/reperfusion injury on cardiac metabolism. Richard joined Zeneca Pharmaceuticals, Safety of Medicines Group in 1996 as a Study Director, and then Project Toxicologist across multiple therapy areas, from early discovery through to market. As Lead Toxicologist for Oncology, Richard was a member of both the Drug Safety and Metabolism, and Oncology Leadership teams with responsibility for safety across the AZ oncology portfolio. In this senior role he provided leadership and mentoring support to other project toxicologists. Richard has worked on many drug platforms over this time including small molecules, biologics, proteins and oligonucleotides and has been involved in bringing over 30 new candidate drugs into clinical trials and 5 to marketing approval.

ApconiX Welcomes Ian Slater to the Team

ApconiX is delighted to welcome Ian Slater to the team.  Ian has spent many years in the pharmaceutical industry as a toxicology Study Director and Study Monitor and he joins our nonclinical study monitoring team.  Ian was previously an Associate Principal Toxicologist in the Regulatory Safety group at AstraZeneca and has a wealth of experience [...]

By |2019-04-25T14:22:47+01:00April 30th, 2019|Uncategorised|Comments Off on ApconiX Welcomes Ian Slater to the Team

ApconiX at SOT 2019

Today is the last day of Society of Toxicology 58th Annual Meeting & Expo 2019.  It's been a fabulous few days in Baltimore with the ApconiX team meeting up with old friends and new.  Brilliant talks by Dr Jane Barber, Dr Paul Duffy and Dr Michael Morton. "All the presentations were excellent. Lots of great [...]

By |2019-03-13T14:55:37+01:00March 13th, 2019|Events|Comments Off on ApconiX at SOT 2019

ApconiX Celebrates Opening Swedish Office

Dr Michael Morton, Professor Ruth Roberts and Dr Richard Knight flew to Sweden to celebrate the opening of ApconiX AB in Gothenburg by sharing coffee and cake (fika) with our fellow tenants in the BioVentureHub. Experienced toxicologists Drs Steffen Ernst and Björn Dahl, who are based at the new Swedish office, joined the three Directors [...]

By |2019-03-13T11:07:12+01:00March 13th, 2019|Events|Comments Off on ApconiX Celebrates Opening Swedish Office

SOT 58th Annual Meeting & ToxExpo – 2613: Talk by Dr Paul Duffy of ApconiX

At the Society of Toxicology 58th Annual Meeting and ToxExpo from March 10th to 14th at the Baltimore Convention Center, Dr Paul Duffy of ApconiX will be giving a talk as part of the Safety Assessment: Pharmaceutical—Drug Development I Platform on Wednesday March 13th 9:15am – 9:30am in Convention Center Room 321. New Opportunities for a Psychoactive Psilocybin in [...]

By |2019-03-04T17:31:07+01:00March 4th, 2019|Toxicology, Events|Comments Off on SOT 58th Annual Meeting & ToxExpo – 2613: Talk by Dr Paul Duffy of ApconiX

ApconiX Exhibiting at SOT Booth Number 2610

ApconiX will be exhibiting on booth number 2610 at the Society of Toxicology 58th Annual Meeting and ToxExpo in Baltimore between 10th and 14th of March. Ruth Roberts, Richard Knight, Michael Morton, Jane Barber, Paul Duffy, Steffen Ernst and Marie Cumberbatch will be attending the conference. Jane, Paul and Mike are all speaking.  Poster presentations [...]

By |2019-02-27T13:32:48+01:00February 20th, 2019|Toxicology, Events|Comments Off on ApconiX Exhibiting at SOT Booth Number 2610

ApconiX Opens a New Office in Sweden

ApconiX is excited to announce the opening of our new office in Sweden.  The subsidiary ApconiX AB will be located at AstraZeneca’s BioVentureHub in Gothenburg. ApconiX was formed by Dr Richard Knight, Dr Michael Morton and Professor Ruth Roberts in 2015 and is based at Alderley Park in Cheshire, U.K.   The co-founders have established a [...]

By |2019-02-27T14:36:25+01:00February 7th, 2019|Ion Channels, Target Safety Assessments, Toxicology, Events|Comments Off on ApconiX Opens a New Office in Sweden

ApconiX Welcomes Steve Snyder

ApconiX is delighted to welcome Steve Snyder to the team.  Steve joins the nonclinical study monitoring team and is based in Florida in the United States. Having worked at Wyeth, Eli Lilly, McNeil Pharmaceutical and Charles River, Steve has a wealth of experience in preclinical toxicology as both an outsourcing customer and provider.  He is [...]

By |2019-02-06T09:53:22+01:00February 6th, 2019|Nonclinical Study Monitoring, Careers|Comments Off on ApconiX Welcomes Steve Snyder

ApconiX Welcomes Dr Bjorn Dahl

ApconiX is delighted to welcome Dr Björn Dahl to the team, who joins our new Swedish office at AstraZeneca’s BioVentureHub in Gothenburg. Björn is a highly respected and experienced toxicologist, having been the co-chair of the European Federation Pharmaceutical Industry Association (EFPIA) Preclinical Development Expert Working Group and served as the EFPIA topic lead in [...]

By |2019-05-08T12:20:38+01:00February 6th, 2019|Toxicology, Careers|Comments Off on ApconiX Welcomes Dr Bjorn Dahl

Wishing Everyone Happy Holidays

The ApconiX team enjoyed a festive lunch at the Coach and Four in Wilmslow this Christmas. We'd all like to take this opportunity to wish everyone Happy Holidays, a Merry Christmas and a very Happy and Prosperous New Year. Here's to making lots of better decisions in 2019!

By |2018-12-21T17:20:41+01:00December 16th, 2018|Events|Comments Off on Wishing Everyone Happy Holidays

Choosing the right non-clinical CRO

Non-clinical contract research organisations (CROs) are an integral part of modern drug development. For any novel agent, delivery of GLP toxicity data to support clinical trials is a crucial step that requires a professional organisation with dedicated management, infrastructure and a broad array of technical and scientific skills. In selecting a CRO, the sponsor typically [...]

By |2018-09-12T14:07:14+01:00September 19th, 2018|Toxicology, Press|Comments Off on Choosing the right non-clinical CRO